Photographer: Scott Eisen/Bloomberg

Pfizer Opts Not to Split, Putting Focus on M&A and New Drugs

  • ‘More transactions seem likely,’ Bernstein analyst says
  • Drugmaker had signaled recently it may stay together

Pfizer Inc. decided not to split in two separate companies, opting against what could have been one of the biggest breakups in the drug industry’s history after years of what it called an “extensive evaluation.”

To continue reading this article you must be a Bloomberg Professional Service Subscriber.